Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M.R. Stockler
Patients' Preferences for Adjuvant Sorafenib After Resection of Renal Cell Carcinoma in the SORCE Trial: What Makes It Worthwhile?
Annals of Oncology
Medicine
Oncology
Hematology
Related publications
Adjuvant Therapy After Nephrectomy for Renal Cell Carcinoma
Asia-Pacific Journal of Clinical Oncology
Medicine
Oncology
Sorafenib With Interleukin-2 vs Sorafenib Alone in Metastatic Renal Cell Carcinoma: The ROSORC Trial
British Journal of Cancer
Cancer Research
Oncology
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After Nephrectomy
New England Journal of Medicine
Medicine
Critical Appraisal of Sorafenib in the Treatment of Chinese Patients With Renal Cell Carcinoma
OncoTargets and Therapy
Oncology
Pharmacology
Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Clinical Cancer Research
Cancer Research
Oncology
Effects of Postoperative Adjuvant Therapies for Renal Cell Carcinoma
Japanese Journal of Urology
Urology
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
The Lancet
Medicine
Kidney Open Resection in Renal Cell Carcinoma
Herald Urology
A Randomized Controlled Trial on Patients With or Without Adjuvant Autologous Cytokine-Induced Killer Cells After Curative Resection for Hepatocellular Carcinoma
OncoImmunology
Oncology
Allergy
Immunology
